Introduction
============

Lumbar spinal stenosis (LSS) is a progressive degenerative narrowing of the central spinal canal and/or lateral neuroforamen that commonly leads to neurogenic claudication by compression of the spinal nerves and associated vasculature.[@b1-cia-6-227] LSS currently affects 1 million people in the United States and is the most common indication for spinal surgery in the elderly.[@b2-cia-6-227] While some patients with LSS are asymptomatic, most present with leg pain, numbness, and tingling that is exacerbated with ambulation and extension movements of the spinal column. Ultimately, these symptoms result in lower quality of life and impaired functional capacity.[@b3-cia-6-227]

Despite the lack of convincing evidence to support their use, initial management of mild radicular symptoms focuses on nonsurgical options and includes activity modification, physical therapy, analgesic and anti-inflammatory medications, and epidural spinal injections.[@b4-cia-6-227] However, none of these therapies has demonstrated long-term effectiveness since they do not alter the course of disease progression.[@b5-cia-6-227],[@b6-cia-6-227] As the disease worsens to yield moderate symptoms, patients must tolerate progressively persistent pain and functional impairment since no additional treatment options are available. Ultimately, as the disease advances to produce chronic and severe symptoms, open spinal surgery such as decompressive laminectomy with or without fusion is often required to alleviate symptoms.[@b7-cia-6-227],[@b8-cia-6-227]

Minimally invasive lumbar procedures represent a viable alternative that addresses the therapeutic gap for patients with moderate radicular symptoms. In particular, interspinous process decompression utilizes a spacer that is implanted between contiguous spinous processes to limit back extension at the symptomatic level, thereby improving patient symptoms.[@b9-cia-6-227] Potential advantages of this procedure versus other surgical procedures include lower neural injury risk, ability to intervene earlier in the disease process before symptoms become debilitating, and preservation of anatomical structures which allows the option of more invasive surgery in the future, should severe symptoms recur or further mechanical changes ensue. The X-STOP^®^ Interspinous Process Decompression System (Medtronic, Inc, Minneapolis, MN) has been extensively studied in clinical trials,[@b10-cia-6-227]--[@b16-cia-6-227] although reports with other spacers are less common.[@b17-cia-6-227]--[@b21-cia-6-227] Despite overall favorable results with these devices in anatomically suitable patients, the clinical benefit of interspinous spacers is debatable given the paucity of available long-term data and the risk for device-related complications.[@b22-cia-6-227],[@b23-cia-6-227] This study was conducted to evaluate 2-year clinical outcomes in patients with moderate LSS who were treated with a novel, minimally invasive interspinous spacer.

Materials and methods
=====================

Patients
--------

This single-arm prospective study enrolled 53 patients with moderate LSS between July 2007 and March 2008. All patients were treated with the Superion^®^ Interspinous Spacer (VertiFlex, San Clemente, CA). Inclusion criteria for this study included: (1) diagnosis of moderate LSS, defined as 25%--50% reduction in lateral/central foramen diameter compared with adjacent levels and radiographic evidence (magnetic resonance imaging or computed tomography) of thecal sac and/or cauda equine compression, nerve root impingement by either osseous or nonosseous elements, and/or hypertrophic facets with canal encroachment; (2) persistent leg, buttock, or groin pain, with or without back pain, that was relieved by lumbar flexion; and (3) unsuccessful nonoperative treatment for at least 3 months. Exclusion criteria included (1) axial back pain only, (2) grade II--V spondylolisthesis, (3) unremitting back pain in any spinal position, (4) active systemic disease that may affect the welfare of the patient, (5) vertebral osteoporosis or history of vertebral fracture, and (6) pregnant or lactating female. The procedures used in this clinical study were in accordance with the recommendations of the Helsinki Declaration, and each patient provided written informed consent before surgery.

Intervention
------------

The Superion device is a single-piece, self-expanding titanium implant that is delivered via percutaneous access and deployed between the spinous processes of the symptomatic vertebral levels ([Figure 1A and B](#f1-cia-6-227){ref-type="fig"}). The minimally invasive procedure began with the patient lying prone on a radiolucent table with the lumbar spine in a neutral or slightly flexed position. Using fluoroscopic guidance or direct visualization, the symptomatic level was identified and a 12--15 mm midline incision was made. The supraspinous ligament was longitudinally dissected at the symptomatic level and was then dilated to ensure adequate room to maneuver within the interspinous space. A cannula was inserted over the dilator, and proper alignment and depth were ensured before dilator removal. Next, an interspinous gauge was inserted through the cannula to determine proper implant size selection. Final midline positioning was confirmed under fluoroscopy.

The appropriately sized spacer was delivered through the cannula using a device inserter that loaded the implant, inserted it into the interspinous space via the cannula, and then deployed the implant. Proper device placement was confirmed with fluoroscopy. Finally, the inserter and cannula were removed, and the incision was sutured in a standard fashion.

Outcomes
--------

Patients were assessed pre-treatment and then returned for follow-up visits at 6 weeks and at 1 and 2 years post-treatment. Axial and extremity pain severity was measured with an 11-point (0--10) numeric pain scale at pre-treatment and postoperatively only. The Zurich Claudication Questionnaire (ZCQ) was utilized to assess patient-reported measures of symptom severity, physical function, and patient satisfaction. [@b14-cia-6-227] Back-specific functional disability was measured with the Oswestry Disability Index (ODI) ( version 2) on a 0%--100% scale.[@b24-cia-6-227] Health-related quality of life was assessed with the SF-12^®^, version 2, (Medical Outcomes Trust, Hanover, NH) and Physical Component Summary (PCS) and Mental Component Summary (MCS) scores were recorded.[@b25-cia-6-227] Safety was assessed by incidence of reported adverse events through the 2-year follow-up period.

Data analysis
-------------

Data were analyzed using Predictive Analytics Software, version 18 (SPSS, Inc, Chicago, IL). Patients included in this report had 2-year data available for at least one of the following variables: axial pain, extremity pain, ZCQ, ODI, PCS, and MCS. Continuous data were reported as mean ± standard deviation, and categorical data were reported as frequencies and percentages. Longitudinal changes in patient outcomes were analyzed with repeated measures analysis of variance. Clinical success at each follow-up period was defined as a ≥30% improvement in pain scores,[@b26-cia-6-227],[@b27-cia-6-227] ≥0.5 point improvement in ZCQ symptom severity and physical function,[@b14-cia-6-227] ZCQ patient satisfaction score ≤2.5,[@b14-cia-6-227] ≥30% improvement in ODI,[@b26-cia-6-227],[@b28-cia-6-227] ≥5.7-point improvement in PCS,[@b29-cia-6-227] and ≥6.3-point improvement in MCS.[@b29-cia-6-227]

Results
=======

Patient characteristics included mean age of 70 ± 11 years, 45% female, 98% (52 of 53) with single level disease, moderate disability, and severe back pain with a mean duration of 30 ± 31 months. Implant size ranged from 8 to 16 mm with the 11--13 mm devices accounting for two-thirds of implants ([Table 1](#t1-cia-6-227){ref-type="table"}).

Axial and extremity pain severity
---------------------------------

Axial pain decreased 54% (*P* \< 0.001) from 8.9 ± 1.4 at pre-treatment to 4.1 ± 3.4 postoperatively ([Figure 2A](#f2-cia-6-227){ref-type="fig"}). At the postoperative follow-up, 73% (29 of 40) of patients achieved the clinical success threshold of a ≥30% improvement ( [Figure 2B](#f2-cia-6-227){ref-type="fig"}). Similar improvements in extremity pain were realized with a mean improvement of 54% from 8.7 ± 1.9 at pre-treatment and 4.1 ± 3.2 postoperatively (*P* \< 0.001). Extremity pain clinical success was 74% (28 of 38) postoperatively.

ZCQ
---

ZCQ symptom severity scores improved 43% (*P* \< 0.001), and ZCQ physical function improved 44% (*P* \< 0.001) from pre-treatment to 2 years post-treatment ([Figure 3A](#f3-cia-6-227){ref-type="fig"}). The mean ZCQ patient satisfaction score was 1.9 at all follow-up visits. When using the standard criteria of an improvement of 0.5 points or greater to define 2-year clinical success, 83% (43 of 52) of patients achieved ZCQ symptom severity clinical success, and 89% (47 of 53) of patients achieved ZCQ physical function clinical success. Patient satisfaction clinical success (score ≤2.5) at 2 years was 87% (46 of 53). The proportion of patients that achieved at least two of three clinical success criteria at 2 years was 87% (45 of 52) ([Figure 3B](#f3-cia-6-227){ref-type="fig"}).

Back-specific functional impairment
-----------------------------------

A statistically significant 50% improvement (*P* \< 0.001) in back function was noted through 2 years post-treatment ( [Figure 4A](#f4-cia-6-227){ref-type="fig"}). When using the standard criteria of an improvement of 30% or greater to define clinical success, 75% (39 of 52) of patients achieved ODI clinical success at 2 years ([Figure 4B](#f4-cia-6-227){ref-type="fig"}).

Quality of life assessment
--------------------------

PCS and MCS each improved 40% (*P* \< 0.001) from pre- treatment to 2 years ([Figure 5A](#f5-cia-6-227){ref-type="fig"}). Through 2 years, MCS clinical success was achieved in 80% (40 of 50) of patients, while PCS clinical success was achieved in 78% (39 of 50) of patients ([Figure 5B](#f5-cia-6-227){ref-type="fig"}).

Adverse events
--------------

No device infection, implant breakage, migration, or pull-out was observed through the 2-year follow-up visit. Two (3.8%) patients underwent explant with subsequent laminectomy due to persistent radicular symptoms.

Discussion
==========

The Superion Interspinous Spacer is a novel, minimally invasive device that offers excellent safety and effectiveness for the patient with intermittent neurogenic claudication secondary to moderate LSS based on the 2-year outcomes reported in the current study. All clinical markers of pain, function, and health-related quality of life improved by approximately 50% over the 2-year follow-up period.

The outcomes observed in this study compare favorably to those reported with the X-STOP spacer with improvements of 44% for ZCQ physical function, 45% for ZCQ symptom severity, 36% for extremity pain, and 38% for ODI in these studies.[@b12-cia-6-227],[@b16-cia-6-227] Furthermore, the 3.8% reintervention rate in the current series approximates the 1.0%--4.6% reintervention rate reported in the largest X-STOP trials.[@b12-cia-6-227],[@b16-cia-6-227]

The safety and effectiveness of the Superion device also appears to be similar to that of laminectomy. Success rates of 74%--89% were observed, depending on the outcome, in the current series. Overall success rates with laminectomy range from 26% to 100%.[@b8-cia-6-227],[@b30-cia-6-227]--[@b32-cia-6-227] No device- complications were observed in the current series, although persistent radicular symptoms requiring device explant were reported in two (3.8%) patients. Common complications of laminectomy are dural tear (6%), infection (3%), and deep vein thrombosis (3%).[@b8-cia-6-227]

Despite the low incidence of complications in this series, several concerns have been raised regarding use of interspinous spacers including device subsidence, spinous process fracture, treated segment destabilization, and adjacent segment degeneration. Although concern for device subsidence has been acknowledged with interspinous spacers, no known study has reported this complication to date. Spinous process fracture has been noted in 0%--6% of patients treated with interspinous spacers who were followed with plain radiographs,[@b16-cia-6-227],[@b33-cia-6-227],[@b34-cia-6-227] although one study reported a 29% fracture incidence with computed tomographic imaging.[@b35-cia-6-227] Low lumbar bone mineral density has been suggested as a potential risk factor for device fracture, and severe osteoporosis is a common exclusion criterion for these devices.[@b35-cia-6-227] Destabilization of the treated segment is purported as a potential risk of interspinous spacer treatment. Biomechanical studies have yielded mixed conclusions on the effect of an implanted interspinous spacer on segmental range of motion,[@b36-cia-6-227],[@b37-cia-6-227] and no definitive evidence from human trials currently exists. Despite concern for adjacent segment degeneration with long-term interspinous spacer implant, no biomechanical or human study has demonstrated that an interspinous spacer has deleterious effects on adjacent levels.[@b36-cia-6-227],[@b38-cia-6-227],[@b39-cia-6-227] Overall, complications with interspinous spacers are uncommon and seem to be primarily attributable to improper patient selection.[@b34-cia-6-227]

The appropriateness of patients with low-grade slip for interspinous spacer treatment is debatable. The study of Verhoof and colleagues[@b40-cia-6-227] investigated interspinous spacer use in 12 patients (9 with grade I slip and 2 with grade II slip) and reported a 58% reintervention rate within 2 years. In the largest study in interspinous spacer use in patients with low-grade slip, patients treated with interspinous spacer (n = 42) had a similar reintervention rate (12%) as subjects treated nonoperatively (n = 33).[@b33-cia-6-227] Implantation of an interspinous spacer prevents motion at the implanted level[@b41-cia-6-227] and results in no progression of spondylolisthesis over time.[@b33-cia-6-227] Most studies of interspinous spacers allow enrolment of patients with grade I slip, and no compelling evidence exists to exclude these patients from treatment consideration.[@b23-cia-6-227],[@b34-cia-6-227]

Patient selection is critical to ensure a high probability of treatment success with an interspinous spacer. Patients must have confirmatory imaging evidence of LSS, relief of symptoms during lumbar flexion, adequate vertebral bone mineral density, and must be nonresponsive to conservative care efforts in order to realize maximum benefit from this therapy. The favorable safety profile observed with this interspinous spacer for treatment of LSS is attributed not only to careful patient selection but also because resection of the posterior spinal elements was not required, and therefore, motion of the lumbar spine is preserved.

The primary limitation of this study was the lack of a concurrent control group, which may have introduced bias into the interpretation of study outcomes. However, the magnitude of benefit with the interspinous spacer was so dramatic that nonspecific study effects such as placebo could not reasonably account for all of the noted clinical improvement.

Interspinous spacer implant with the Superion device is a safe and effective treatment option for carefully selected patients with moderate LSS who are unresponsive to conservative care but are not yet eligible candidates for traditional spinal surgery such as laminectomy.
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![(**A**) Postero-anterior and (**B**) lateral radiographic images showing a properly placed Superion^®^ Interspinous Spacer (VertiFlex, Inc, San Clemente, CA).](cia-6-227f1){#f1-cia-6-227}

![(**A**) Improvement in postoperative axial and extremity pain scores (mean ± 95% confidence interval). (**B**) Clinical success rates (≥30% improvement).](cia-6-227f2){#f2-cia-6-227}

![(**A**) Improvement in Zurich Claudication Questionnaire scores through 2 years post-treatment (mean ± 95% confidence interval). (**B**) Clinical success rates (≥0.5 points symptom severity and physical function improvement, ≤2.5 points patient satisfaction) through 2 years post-treatment.](cia-6-227f3){#f3-cia-6-227}

![(**A**) Improvement in ODI scores through 2 years post-treatment (mean ± 95% confidence interval). (**B**) Clinical success rates (≥30% improvement) through 2 years post-treatment.\
**Abbreviation:** ODI, Oswestry Disability Index.](cia-6-227f4){#f4-cia-6-227}

![(**A**) Improvement in PCS and MCS scores through 2 years post-treatment (mean ± 95% confidence interval). (**B**) Success rates (≥5.7 points PCS improvement, ≥6.3 points MCS improvement) through 2 years post-treatment.\
**Abbreviations:** MCS, Mental Component Summary; PCS, Physical Component Summary.](cia-6-227f5){#f5-cia-6-227}

###### 

Patient characteristics

  Characteristic                                N    Value
  --------------------------------------------- ---- -----------
  Age, mean ± SD, years                         53   70 ± 11
  Female, n (%)                                 53   24 (45)
  Previous spine operation, n (%)               52   4 (8)
  Current smoker, n (%)                         53   4 (8)
  Duration of symptoms, mean ± SD, months       47   30 ± 31
  Axial pain score, mean ± SD                   45   8.8 ± 1.9
  Extremity pain score, mean ± SD               41   8.8 ± 1.9
  ZCQ symptom severity, mean ± SD               52   3.4 ± 0.6
  ZCQ physical function, mean ± SD              53   3.2 ± 0.4
  Oswestry Disability Index, mean ± SD, %       52   57 ± 14
  Physical Component Summary score, mean ± SD   53   31 ± 7
  Mental Component Summary score, mean ± SD     53   33 ± 8

**Abbreviations:** SD, standard deviation; ZCQ, Zurich Claudication Questionnaire.
